Attributes | Values |
---|
rdf:type
| |
Description
| - Background: The risk of POF onset depends mainly on womens age and foliculogenesis status in ovary, chemotherapy (CT) regimen used and cumulative dose of single cytotoxic agents. Aims: Aim of this prospective case-control study is evaluation of gonadoliberine analogues (GnRHa) administration to patients with Hodgkins lymphoma (HL) during chemotherapy and prevention of ovarian damage depending upon CT dose and regimen. Methods: Study group consists of 72 patients in fertile age with HL by curative CT together with GnRHa administration according standardized protocol. Group A received ABVD, group B baseline BEACOPP and ABVD in combination, group C dose escalated BEACOPP regimen. Results: In study group with GnRHa administration during CT there was statistical significantly less cases with POF (38.2 %) in 6 month after end of CT than in control group (73.4 %). After 12 month POF was detected in 48.8 % of cases versus 69.3 % in control group.
- Background: The risk of POF onset depends mainly on womens age and foliculogenesis status in ovary, chemotherapy (CT) regimen used and cumulative dose of single cytotoxic agents. Aims: Aim of this prospective case-control study is evaluation of gonadoliberine analogues (GnRHa) administration to patients with Hodgkins lymphoma (HL) during chemotherapy and prevention of ovarian damage depending upon CT dose and regimen. Methods: Study group consists of 72 patients in fertile age with HL by curative CT together with GnRHa administration according standardized protocol. Group A received ABVD, group B baseline BEACOPP and ABVD in combination, group C dose escalated BEACOPP regimen. Results: In study group with GnRHa administration during CT there was statistical significantly less cases with POF (38.2 %) in 6 month after end of CT than in control group (73.4 %). After 12 month POF was detected in 48.8 % of cases versus 69.3 % in control group. (en)
|
Title
| - Prevention of ovarian damage during chemotherapy by gonadoliberine analogues administration
- Prevention of ovarian damage during chemotherapy by gonadoliberine analogues administration (en)
|
skos:prefLabel
| - Prevention of ovarian damage during chemotherapy by gonadoliberine analogues administration
- Prevention of ovarian damage during chemotherapy by gonadoliberine analogues administration (en)
|
skos:notation
| - RIV/00216224:14110/07:00019138!RIV10-MZ0-14110___
|
http://linked.open...avai/riv/aktivita
| |
http://linked.open...avai/riv/aktivity
| |
http://linked.open...vai/riv/dodaniDat
| |
http://linked.open...aciTvurceVysledku
| |
http://linked.open.../riv/druhVysledku
| |
http://linked.open...iv/duvernostUdaju
| |
http://linked.open...titaPredkladatele
| |
http://linked.open...dnocenehoVysledku
| |
http://linked.open...ai/riv/idVysledku
| - RIV/00216224:14110/07:00019138
|
http://linked.open...riv/jazykVysledku
| |
http://linked.open.../riv/klicovaSlova
| - Hodgkins lymphoma; gonadoliberine analogues; premature ovarian failure (en)
|
http://linked.open.../riv/klicoveSlovo
| |
http://linked.open...ontrolniKodProRIV
| |
http://linked.open...in/vavai/riv/obor
| |
http://linked.open...ichTvurcuVysledku
| |
http://linked.open...cetTvurcuVysledku
| |
http://linked.open...vavai/riv/projekt
| |
http://linked.open...UplatneniVysledku
| |
http://linked.open...iv/tvurceVysledku
| - Crha, Igor
- Huser, Martin
- Ventruba, Pavel
- Král, Zdeněk
- Vorlíček, Jiří
- Šmardová, Lenka
|
http://localhost/t...ganizacniJednotka
| |